High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome - PubMed (original) (raw)

. 2011 Sep;147(9):1110-2.

doi: 10.1001/archdermatol.2011.239.

Hideaki Watanabe, Mikiko Tohyama, Kazunari Sugita, Masafumi Iijima, Koji Hashimoto, Yoshiki Tokura, Youichi Nishimura, Hiromi Doi, Miki Tanioka, Yoshiki Miyachi, Kenji Kabashima

• PMID: 21931056
• DOI: 10.1001/archdermatol.2011.239

High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome

Saeko Nakajima et al. Arch Dermatol. 2011 Sep.

No abstract available

PubMed Disclaimer

Similar articles

• Toxic epidermal necrolysis in Stevens--Johnson syndrome.
  Assaad D, From L, Ricciatti D, Shapero H. Assaad D, et al. Can Med Assoc J. 1978 Jan 21;118(2):154-6. Can Med Assoc J. 1978. PMID: 757383 Free PMC article.
• Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.
  Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, Shimizu H. Fujita Y, et al. J Am Acad Dermatol. 2011 Jul;65(1):65-8. doi: 10.1016/j.jaad.2010.04.042. Epub 2011 Apr 19. J Am Acad Dermatol. 2011. PMID: 21507517
• Stevens-Johnson syndrome and toxic epidermal necrolysis.
  Prendiville J. Prendiville J. Adv Dermatol. 2002;18:151-73. Adv Dermatol. 2002. PMID: 12528405 Review. No abstract available.
• European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome.
  Fritsch P. Fritsch P. Eur J Dermatol. 2008 Mar-Apr;18(2):216-7. doi: 10.1684/ejd.2008.0382. Eur J Dermatol. 2008. PMID: 18424404 Review. No abstract available.
• [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
  Rzany B, Mockenhaupt M, Baur S, Stocker U, Schöpf E. Rzany B, et al. Hautarzt. 1993 Aug;44(8):549-54; quiz 554-6. Hautarzt. 1993. PMID: 8376113 Review. German. No abstract available.

Cited by

• Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.
  Shah H, Parisi R, Mukherjee E, Phillips EJ, Dodiuk-Gad RP. Shah H, et al. Am J Clin Dermatol. 2024 Sep 15. doi: 10.1007/s40257-024-00889-6. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 39278968 Review.
• Diagnostic Tools and Biomarkers for Severe Drug Eruptions.
  Yoshioka M, Sawada Y, Nakamura M. Yoshioka M, et al. Int J Mol Sci. 2021 Jul 14;22(14):7527. doi: 10.3390/ijms22147527. Int J Mol Sci. 2021. PMID: 34299145 Free PMC article. Review.
• Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN).
  Kuijper EC, French LE, Tensen CP, Vermeer MH, Bouwes Bavinck JN. Kuijper EC, et al. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1957-1971. doi: 10.1111/jdv.16339. Epub 2020 May 15. J Eur Acad Dermatol Venereol. 2020. PMID: 32415695 Free PMC article. Review.
• Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.
  Bellón T. Bellón T. Drug Saf. 2019 Aug;42(8):973-992. doi: 10.1007/s40264-019-00825-2. Drug Saf. 2019. PMID: 31020549 Review.
• Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
  Carr DF, Wang CW, Bellón T, Ressel L, Nwikue G, Shrivastava V, Bergfeld W, Jorgensen AL, Chung WH, Pirmohamed M. Carr DF, et al. Br J Dermatol. 2019 Jul;181(1):166-174. doi: 10.1111/bjd.17610. Epub 2019 Mar 26. Br J Dermatol. 2019. PMID: 30613954 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems